Actinic Keratosis: Update on Field Therapy

Overview

Journal J Clin Aesthet Dermatol

Date 2014 Nov 6

PMID 25371768

Citations 15

Authors

Gary Goldenberg

Marcel Perl

Affiliations

Soon will be listed here.

Abstract

Actinic keratosis is widely considered a field disease that is rarely limited to a single clinically apparent lesion. Field-directed therapies, such as ingenol mebutate, imiquimod, and photodynamic therapy, aim to treat not only clinically visible lesions, but also subclinical disease that is thought to exist along the same continuum as actinic keratosis and squamous cell carcinoma. These field treatments have shown efficacy compared to placebo as well as in long-term follow-up studies when compared to lesion-directed cryotherapy alone. Field therapy in combination with lesion-directed treatment will allow the practitioner to further optimize efficacy as well as patient preference and convenience. As the incidence of nonmelanoma skin cancer continues to rise, these treatment modalities provide new options to halt the progression of actinic keratosis, and thereby reduce the incidence of nonmelanoma skin cancer and its burden on our healthcare system.

Citing Articles

Epidemiology and Management of Actinic Keratosis in France: A General Population Survey (REAKT).

Dreno B, Levy P, Caillet G, Touboul C, Joubert J, Amici J Acta Derm Venereol. 2025; 105:adv42372.

PMID: 39863962 PMC: 11788678. DOI: 10.2340/actadv.v105.42372.

Genome-wide association study of actinic keratosis identifies new susceptibility loci implicated in pigmentation and immune regulation pathways.

Kim Y, Yin J, Huang H, Jorgenson E, Choquet H, Asgari M Commun Biol. 2022; 5(1):386.

PMID: 35449187 PMC: 9023580. DOI: 10.1038/s42003-022-03301-3.

Topical Administration of Terpenes Encapsulated in Nanostructured Lipid-Based Systems.

Lason E Molecules. 2020; 25(23).

PMID: 33297317 PMC: 7730254. DOI: 10.3390/molecules25235758.

Daylight Photodynamic Therapy: An Update.

Lee C, Hsu R, Chen H, Wong T Molecules. 2020; 25(21).

PMID: 33171665 PMC: 7664668. DOI: 10.3390/molecules25215195.

A review of actinic keratosis, skin field cancerisation and the efficacy of topical therapies.

Sinclair R, Baker C, Spelman L, Supranowicz M, MacMahon B Australas J Dermatol. 2020; 62(2):119-123.

PMID: 32840870 PMC: 8247342. DOI: 10.1111/ajd.13447.

References

Gupta A, Paquet M, Villanueva E, Brintnell W . Interventions for actinic keratoses. Cochrane Database Syst Rev. 2012; 12:CD004415. PMC: 6599879. DOI: 10.1002/14651858.CD004415.pub2. View

Joseph M, Zulueta W, Kennedy P . Squamous cell carcinoma of the skin of the trunk and limbs: the incidence of metastases and their outcome. Aust N Z J Surg. 1992; 62(9):697-701. DOI: 10.1111/j.1445-2197.1992.tb07065.x. View

Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E . A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007; 157 Suppl 2:34-40. DOI: 10.1111/j.1365-2133.2007.08271.x. View

Hadley G, Derry S, Moore R . Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol. 2006; 126(6):1251-5. DOI: 10.1038/sj.jid.5700264. View

Stockfleth E, Ferrandiz C, Grob J, Leigh I, Pehamberger H, Kerl H . Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol. 2008; 18(6):651-9. DOI: 10.1684/ejd.2008.0514. View

Padilla R, Sebastian S, Jiang Z, Nindl I, Larson R . Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. Arch Dermatol. 2010; 146(3):288-93. DOI: 10.1001/archdermatol.2009.378. View

Schmieder G, Huang E, Jarratt M . A multicenter, randomized, vehicle-controlled phase 2 study of blue light photodynamic therapy with aminolevulinic acid HCl 20% topical solution for the treatment of actinic keratoses on the upper extremities: the effect of occlusion during the drug.... J Drugs Dermatol. 2013; 11(12):1483-9. View

Brougham N, Dennett E, Cameron R, Tan S . The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. J Surg Oncol. 2012; 106(7):811-5. DOI: 10.1002/jso.23155. View

Ratushny V, Gober M, Hick R, Ridky T, Seykora J . From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest. 2012; 122(2):464-72. PMC: 3266779. DOI: 10.1172/JCI57415. View

10.

Angell-Petersen E, Sorensen R, Warloe T, Soler A, Moan J, Peng Q . Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Invest Dermatol. 2005; 126(2):265-71. DOI: 10.1038/sj.jid.5700048. View

11.

Challacombe J, Suhrbier A, Parsons P, Jones B, Hampson P, Kavanagh D . Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol. 2006; 177(11):8123-32. DOI: 10.4049/jimmunol.177.11.8123. View

12.

Lebwohl M, Swanson N, Anderson L, Melgaard A, Xu Z, Berman B . Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012; 366(11):1010-9. DOI: 10.1056/NEJMoa1111170. View

13.

Ogbourne S, Suhrbier A, Jones B, Cozzi S, Boyle G, Morris M . Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 2004; 64(8):2833-9. DOI: 10.1158/0008-5472.can-03-2837. View

14.

Thai K, Fergin P, Freeman M, Vinciullo C, Francis D, Spelman L . A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol. 2004; 43(9):687-92. DOI: 10.1111/j.1365-4632.2004.02056.x. View

15.

Jorizzo J, Markowitz O, Lebwohl M, Bourcier M, Kulp J, Meng T . A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J Drugs Dermatol. 2010; 9(9):1101-8. View

16.

Hsi R, Rosenthal D, Glatstein E . Photodynamic therapy in the treatment of cancer: current state of the art. Drugs. 1999; 57(5):725-34. DOI: 10.2165/00003495-199957050-00005. View

17.

Neidecker M, Davis-Ajami M, Balkrishnan R, Feldman S . Pharmacoeconomic considerations in treating actinic keratosis. Pharmacoeconomics. 2009; 27(6):451-64. DOI: 10.2165/00019053-200927060-00002. View

18.

Criscione V, Weinstock M, Naylor M, Luque C, Eide M, Bingham S . Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer. 2009; 115(11):2523-30. DOI: 10.1002/cncr.24284. View

19.

Dirschka T, Radny P, Dominicus R, Mensing H, Bruning H, Jenne L . Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br J Dermatol. 2012; 168(4):825-36. PMC: 3660784. DOI: 10.1111/bjd.12158. View

20.

Hensen P, Muller M, Haschemi R, Stander H, Luger T, Sunderkotter C . Predisposing factors of actinic keratosis in a North-West German population. Eur J Dermatol. 2009; 19(4):345-54. DOI: 10.1684/ejd.2009.0706. View